Alliancebernstein L.P. Buys 1,758,657 Shares of AbbVie Inc. $ABBV

Alliancebernstein L.P. lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 31.8% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 7,281,327 shares of the company’s stock after buying an additional 1,758,657 shares during the quarter. Alliancebernstein L.P. owned about 0.41% of AbbVie worth $1,685,918,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Ameriprise Financial Inc. raised its stake in AbbVie by 4.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company’s stock worth $2,241,363,000 after purchasing an additional 408,426 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its holdings in AbbVie by 207.9% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 32,481 shares of the company’s stock valued at $7,521,000 after purchasing an additional 21,931 shares during the period. New England Asset Management Inc. grew its position in shares of AbbVie by 0.6% during the 3rd quarter. New England Asset Management Inc. now owns 22,365 shares of the company’s stock worth $5,178,000 after purchasing an additional 125 shares in the last quarter. AQR Capital Management LLC grew its position in shares of AbbVie by 55.0% during the 3rd quarter. AQR Capital Management LLC now owns 926,842 shares of the company’s stock worth $209,652,000 after purchasing an additional 328,850 shares in the last quarter. Finally, Credit Agricole S A bought a new position in shares of AbbVie during the third quarter worth approximately $169,621,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Phase‑1 data for ABBV‑295 reported as encouraging — supports pipeline optionality beyond core brands and is constructive for long‑term revenue upside. AbbVie Reports Promising Results from Phase 1 Study of ABBV-295
• Positive Sentiment: AbbVie advanced a risankizumab dosing study, signaling continued investment in immunology — reinforces management’s growth strategy in a key therapeutic area. AbbVie Advances Risankizumab Dosing Study, Signaling Ongoing Immunology Investment
• Positive Sentiment: RBC Capital started coverage with an Outperform and $260 price target — a bullish institutional view that supports upside versus current levels. RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages
• Positive Sentiment: Consensus analyst stance remains supportive (“Moderate Buy”), which provides a baseline of buy‑side conviction. AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Allergan Aesthetics‑affiliated providers earned top rankings in NY (beneficial for Allergan Aesthetics’ commercial reputation, but limited immediate impact on ABBV stock). New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row
• Neutral Sentiment: Features and listicles (e.g., halal/debt‑free stock roundup, retirement income pieces) mention AbbVie but are peripheral to near‑term price movement. Is AbbVie Inc. (ABBV) One of the Debt Free Halal Stocks to Buy?
• Neutral Sentiment: Market reports forecasting growth in bipolar‑depression therapies expand the market opportunity for psychiatric drugs broadly; indirect for AbbVie unless tied to specific assets. Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight
• Negative Sentiment: Shareholder governance concern: reports that the AbbVie CEO’s pay package has spiked above $30M can weigh on sentiment and prompt selling by governance‑focused funds. J&J, AbbVie CEOs See Pay Spike to More Than $30M
• Negative Sentiment: Analyst debate about immunology competition and valuation creates two‑sided risk—some analysts lift targets on growth, others flag competition that could cap upside, encouraging short‑term profit‑taking. How The Narrative For AbbVie (ABBV) Is Shifting On Immunology Growth And Competition Risks

Wall Street Analyst Weigh In

ABBV has been the subject of a number of analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Piper Sandler raised their price objective on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. Finally, BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.25% of the company’s stock.

AbbVie Trading Down 2.5%

Shares of AbbVie stock opened at $219.73 on Friday. The firm’s 50 day moving average is $224.33 and its 200 day moving average is $224.67. The firm has a market capitalization of $388.51 billion, a PE ratio of 93.10, a price-to-earnings-growth ratio of 0.76 and a beta of 0.34. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the firm earned $2.16 EPS. The firm’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.